Patient perceptions of a proton pump inhibitor therapeutic interchange program across the continuum of care

Pharmacotherapy

Volumn 22, Issue 4, 2002, Pages 500-512

  Sodorff, Michelle M ^a,b   Galt, Kimberly A ^a,b   Galt, Michael A ^a,b   Turner, Paul D ^a   Lambrecht, Jason E ^c  

^a SACRED HEART MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c Alegent Immanuel Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; HEALTH PROGRAM; HEALTH SURVEY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT CARE; PATIENT SATISFACTION; PEPTIC ULCER; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CONTINUITY OF PATIENT CARE; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PERCEPTION; PROSPECTIVE STUDIES; PROTON PUMPS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036209822     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.7.500.33677     Document Type: Article

References (49)

1. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention relapse: A randomized, multicenter, double-masked trial
2. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healing gastric ulcer
3. Lansoprazole versus omeprazole in active duodenal ulcer: A double-blind, randomized, comparative study
4. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: A long-term comparative study
5. Lansoprazole in acute treatment of reflux esophagitis
6. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis: The lansoprazole treatment group
7. Therapeutic interchange: A community hospital's approach
8. Outcomes assessment of an inpatient proton pump inhibitor therapeutic interchange program
9. Cost minimization using market growth of a proton pump inhibitor therapeutic interchange program applied in a multihospital integrated health system
10. The quality of care: How can it be assessed?
11. Drugs, foods and other substances in the cause and treatment of reflux esophagitis
12. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease
13. Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits?
14. Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: Six-year follow-up in the Copenhagen male study
15. The general medical health rating: A bedside global rating of medical comorbidity in patients with dementia
16. An exploratory analysis of medication utilization in a medical intensive care unit
17. Clinical markers of asthma severity and risk: Importance of subjective as well as objective factors
18. A guideline for the treatment and prevention of NSAID-induced ulcers
19. Drug interaction facts
20. The impact of gastroesophageal reflux disease on health-related quality of life
21. Methodology in behavioral and psychosocial cancer research: Conceptualizing disease impact and treatment outcomes
22. Operational aspects of quality of life assessment
23. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease
24. Peptic ulcer disease
25. How to survey patients satisfaction
26. Obtaining information on patient satisfaction with hospital care: Mail versus telephone
27. Patient and provider satisfaction with medical care
28. Measurement of patient compliance
29. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly
30. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole
31. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy
32. Current estimates from the national health interview survey, 1991
33. Comprehensive tuberculosis control for patients at high risk for noncompliance
34. The rise and rise of proton pump inhibitor drugs: Patients' perspectives
35. Discordance between physician and patient perceptions in the treatment of diabetes mellitus: A pilot study of the relationship to adherence and glycemic control
36. Important elements of outpatient care: A comparison of patients' and physicians' opinions
37. The sickness impact profile: Development and final revision of a health status measure
38. Rabeprazole a review of its use in acid-related gastrointestinal disorders
39. The new proton pump inhibitor is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
40. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis
41. Decreasing oesophageal acid exposure in patients with GERD a comparison of rabeprazole and omeprazole
42. Formulary management of proton pump inhibitors